Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND, AUG. 14, 2026 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATIONS RELATE TO THE VESTING AND SETTLEMENT OF RSUS PREVIOUSLY GRANTED TO DIRECTORS OF THE COMPANY.

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

ZUG, SWITZERLAND AND BARCELONA, SPAIN, AUGUST 10, 2026OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON BREAKTHROUGH INNOVATIONS TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN NEURO-OPHTHALMOLOGY AND OPHTHALMOLOGY, AND ACCURE THERAPEUTICS, S.L. (ACCURE), A PRIVATE TRANSLATIONAL NEUROSCIENCE R&D COMPANY, TODAY ANNOUNCED THAT OCULIS AND ACCURE HAVE ENTERED INTO AN ASSET PURCHASE AGREEMENT WHEREBY, UPON CLOSING, OCULIS WILL ACQUIRE ALL OF ACCURE'S WORLDWIDE DEVELOPMENT AND COMMERCIAL RIGHTS TO PRIVOSEGTOR. THIS ACQUISITION WILL RESULT IN THE TERMINATION OF OCULIS' EXISTING LICENSE AGREEMENT WITH ACCURE, INCLUDING ASSOCIATED MILESTONE PAYMENTS AND ROYALTIES FOR EACH SUCCESSFUL INDICATION. THIS STRATEGIC TRANSACTION WOULD ENABLE OCULIS TO BETTER HARNESS PRIVOSEGTOR'S POTENTIAL VALUE GOING FORWARD, WITHOUT THE ENCUMBRANCE OF THE LEGACY LICENSE AGREEMENT WITH ACCURE, WHILE RETAINING GREATER ECONOMIC UPSIDE FOR THE ASSET'S FUTURE SUCCESS AS THE COMPANY CONTINUES TO DRIVE PRIVOSEGTOR'S DEVELOPMENT AND PURSUE POTENTIAL EXPANSION OPPORTUNITIES.

OCULIS SIGNS ASSET PURCHASE AGREEMENT WITH ACCURE THERAPEUTICS FOR LEAD CANDIDATE, PRIVOSEGTOR, FORTIFYING OCULIS' POSITION AS AN EMERGING LEADING NEURO-OPHTHALMOLOGY COMPANY

ZUG, SWITZERLAND, AUG. 06, 2026 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON BREAKTHROUGH INNOVATIONS TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN NEURO-OPHTHALMOLOGY AND OPHTHALMOLOGY, TODAY ANNOUNCED RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED AN OVERVIEW OF THE COMPANY'S PROGRESS.

OCULIS REPORTS Q2 2026 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

ZUG, SWITZERLAND, AUG. 03, 2026 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON BREAKTHROUGH INNOVATIONS TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN NEURO-OPHTHALMOLOGY AND OPHTHALMOLOGY, TODAY ANNOUNCED POSITIVE U.S. FOOD AND DRUG ADMINISTRATION (FDA) PRE-IND FEEDBACK REGARDING PRIVOSEGTOR'S CLINICAL DEVELOPMENT PLAN IN ACUTE MULTIPLE SCLEROSIS (MS) RELAPSES.

OCULIS ANNOUNCES POSITIVE FDA PRE-IND FEEDBACK SUPPORTING PRIVOSEGTOR DEVELOPMENT STRATEGY FOR TREATMENT OF ACUTE MULTIPLE SCLEROSIS RELAPSES

ZUG, SWITZERLAND, JULY 08, 2026 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING AND SETTLEMENT OF RSUS PREVIOUSLY GRANTED TO A DIRECTOR OF THE COMPANY.

ZUG, SWITZERLAND, JULY 2, 2026  OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING NEURO-OPHTHALMIC AND OPHTHALMIC DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, ANNOUNCED TODAY THAT OCULIS' MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER VIRTUAL OPHTHALMOLOGY CONFERENCE.

OCULIS TO PARTICIPATE AT THE PIPER SANDLER VIRTUAL OPHTHALMOLOGY CONFERENCE

NEW YORK, JUNE 25, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF OCULIS HOLDING AG ("OCULIS" OR THE "COMPANY") (NASDAQ: OCS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF OCULIS HOLDING AG - OCS

NEW YORK, JUNE 23, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF OCULIS HOLDING AG (OCULIS OR THE COMPANY) (NASDAQ: OCS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT. 7980.

NEW YORK, JUNE 18, 2026 /PRNEWSWIRE/ -- POMERANTZLLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF OCULIS HOLDING AG ("OCULIS" OR THE "COMPANY") (NASDAQ: OCS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JUNE 16, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF OCULIS HOLDING AG (OCULIS OR THE COMPANY) (NASDAQ: OCS). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT. 7980.

Oculis Holding AG

OCS

Price

Financial Reports

No items found.

Press Releases

Oculis Holding AG

OCS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OCS